Terms: = Breast cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
224 results:
1. Conditional generative adversarial network driven radiomic prediction of mutation status based on magnetic resonance imaging of breast cancer.
Huang ZH; Chen L; Sun Y; Liu Q; Hu P
J Transl Med; 2024 Mar; 22(1):226. PubMed ID: 38429796
[TBL] [Abstract] [Full Text] [Related]
2. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
3. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
[TBL] [Abstract] [Full Text] [Related]
4. breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic tp53 mutations and display a unique structural variant size distribution profile.
Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
[TBL] [Abstract] [Full Text] [Related]
5. The role of p53 and ki67 in predicting clinical outcome in breast cancer patients.
Lalkota BP; Srinivasa BJ; Swamy MV; Hazarika D; Jeet BM; Jyothi K; Ghosh M; Sayeed SM; Nasiruddin M; Naik R
J Cancer Res Ther; 2023; 19(2):208-213. PubMed ID: 37006059
[TBL] [Abstract] [Full Text] [Related]
6. Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification.
Saatci O; Akbulut O; Cetin M; Sikirzhytski V; Uner M; Lengerli D; O'Quinn EC; Romeo MJ; Caliskan B; Banoglu E; Aksoy S; Uner A; Sahin O
Cell Death Differ; 2023 May; 30(5):1305-1319. PubMed ID: 36864125
[TBL] [Abstract] [Full Text] [Related]
7. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, p53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
Voutilainen S; Heikkilä P; Bartkova J; Nevanlinna H; Blomqvist C; Bartek J; Mattson J
BMC Cancer; 2022 Dec; 22(1):1298. PubMed ID: 36503417
[TBL] [Abstract] [Full Text] [Related]
8. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative breast cancer.
Kudelova E; Smolar M; Holubekova V; Hornakova A; Dvorska D; Lucansky V; Koklesova L; Kudela E; Kubatka P
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499265
[TBL] [Abstract] [Full Text] [Related]
9. Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor outcome in Male Malignant Germ Cell Tumors.
Timmerman DM; Eleveld TF; Sriram S; Dorssers LCJ; Gillis AJM; Schmidtova S; Kalavska K; van de Werken HJG; Oing C; Honecker F; Mego M; Looijenga LHJ
J Clin Oncol; 2022 Sep; 40(26):3077-3087. PubMed ID: 35442716
[TBL] [Abstract] [Full Text] [Related]
10. Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers.
Xin Z; Li Y; Meng L; Dong L; Ren J; Men J
Math Biosci Eng; 2022 Jan; 19(2):1825-1842. PubMed ID: 35135230
[TBL] [Abstract] [Full Text] [Related]
11. A concise review on the role of BDNF-AS in human disorders.
Ghafouri-Fard S; Khoshbakht T; Taheri M; Ghanbari M
Biomed Pharmacother; 2021 Oct; 142():112051. PubMed ID: 34426254
[TBL] [Abstract] [Full Text] [Related]
12. Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture.
Liverani C; De Vita A; Spadazzi C; Miserocchi G; Cocchi C; Bongiovanni A; De Lucia A; La Manna F; Fabbri F; Tebaldi M; Amadori D; Tasciotti E; Martinelli G; Mercatali L; Ibrahim T
Mol Oncol; 2022 Feb; 16(4):921-939. PubMed ID: 34109737
[TBL] [Abstract] [Full Text] [Related]
13. Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.
Zhou Y; Xu Y; Wang C; Gong Y; Zhang Y; Yao R; Li P; Zhu X; Bai J; Guan Y; Xia X; Yang L; Yi X; Sun Q
Breast Cancer Res Treat; 2021 Aug; 188(3):661-673. PubMed ID: 34003409
[TBL] [Abstract] [Full Text] [Related]
14. CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5.
Nengroo MA; Maheshwari S; Singh A; Verma A; Arya RK; Chaturvedi P; Saini KK; Singh AK; Sinha A; Meena S; Gupta A; Mishra A; Sarkar J; Datta D
Cell Death Dis; 2021 May; 12(5):464. PubMed ID: 33966046
[TBL] [Abstract] [Full Text] [Related]
15. High nuclear TPX2 expression correlates with tp53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability.
Matson DR; Denu RA; Zasadil LM; Burkard ME; Weaver BA; Flynn C; Stukenberg PT
BMC Cancer; 2021 Feb; 21(1):186. PubMed ID: 33622270
[TBL] [Abstract] [Full Text] [Related]
16. Integrative analysis of multi-omics data highlighted tp53 as a potential diagnostic and prognostic biomarker of survival in breast invasive carcinoma patients.
Hameed Y; Ejaz S
Comput Biol Chem; 2021 Jun; 92():107457. PubMed ID: 33610131
[TBL] [Abstract] [Full Text] [Related]
17. Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy.
Kim S; Shin D; Min A; Kim M; Na D; Lee HB; Ryu HS; Yang Y; Woo GU; Lee KH; Lee DW; Kim TY; Lee C; Im SA; Kim JI
J Transl Med; 2021 Jan; 19(1):7. PubMed ID: 33407601
[TBL] [Abstract] [Full Text] [Related]
18. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
Parks RM; Albanghali MA; Syed BM; Green AR; Ellis IO; Cheung KL
Breast Cancer Res Treat; 2021 Feb; 185(3):647-655. PubMed ID: 33226492
[TBL] [Abstract] [Full Text] [Related]
19. Mutant tp53 interacts with BCAR1 to contribute to cancer cell invasion.
Guo AK; Itahana Y; Seshachalam VP; Chow HY; Ghosh S; Itahana K
Br J Cancer; 2021 Jan; 124(1):299-312. PubMed ID: 33144694
[TBL] [Abstract] [Full Text] [Related]
20. Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth.
Chen JY; Li CF; Lai YS; Hung WC
Br J Cancer; 2021 Jan; 124(2):484-493. PubMed ID: 33024266
[TBL] [Abstract] [Full Text] [Related]
[Next]
